MC10, Inc. and AbbVie (NYSE:ABBV) Announce Clinical Trials in Multiple Sclerosis Using the BioStamp nPoint® System
May 14, 2019
For Immediate Release
LEXINGTON, Mass. & NORTH CHICAGO, Ill. — May 14, 2019 — MC10, Inc., a healthcare technology company specializing in wearable digital health sensors, and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the companies are working together on clinical trials designed to explore a range of outcome measures in patients with multiple sclerosis (MS) using the BioStamp nPoint® system.
This innovative, patient-focused endeavor aims to explore the use of data from the nPoint® System in order to provide unique insights into MS clinical studies. “We are excited to work with a world leader in CNS therapies and look forward to exploring novel data and metrics that help to advance clinical development” commented Dr Arthur Combs, Chief Medical Officer of MC10.
The 510(k) cleared BioStamp nPoint System was developed for use in clinical trials and other applications for the continuous collection of physiological data and is optimized for both in-home and in-clinic use. The system reports vital signs, activity and postural classifications and a suite of sleep metrics. The BioStamp nPoint System is in use today by numerous pharmaceutical companies and in academic research across several therapeutic areas.
“We are excited to explore the BioStamp nPoint System’s ability to unobtrusively collect clinically relevant data continuously from subjects in more natural settings. This technology has the potential to improve the quality of data we collect and at the same time reduce the burden on study participants,” commented Dr. Michael Gold, Vice President, Development Neurosciences, of AbbVie.
MC10 is a privately held company focused on improving human health through digital solutions. The company combines conformal BioStamp sensors with clinical analytics to unlock novel insights from physiological data collected from the home or in clinical settings. Our flagship product, BioStamp nPoint, is intended for the clinical research community. MC10 is headquartered in Lexington, MA. Visit MC10 online at www.mc10inc.com.
About Braemar Energy Ventures
Founded in 2003, Braemar Energy Ventures is a leading venture capital firm focused on transformative energy-tech and related companies contributing to global sustainability and combating climate change. Using sector expertise and experience, Braemar aims to be an engaged partner with its portfolio companies to best help them navigate the path to significant global impact. For more information, visit braemarenergy.com or follow @BraemarEnergy on Twitter.